This includes the use of MEK inhibitors in relapsed CNS tumors with BRAF fusion, use of crizotinib, or other ALK inhibitors in relapsed neuroblastoma with an ALK alteration, and the use of imatinib and dasatinib in Ph (+) ALL [11, 12, 45, 46]. The gene discussed is ALK; the disease is neuroblastoma.